Safety and efficacy of ultrafiltration on heart failure patients with reduced ejection fraction and diuretic resistance: results from a single-center randomized controlled trial / 中华心血管病杂志

Objective: To investigate the safety and efficacy of ultrafiltration on diuretic sensitivity in heart failure patients with reduced ejection fraction and diuretic resistance. Methods: This was a single-center randomized controlled trial. A total of 148 heart failure patients with reduced ejection fraction admitted to the Hospital of Traditional Chinese Medicine of Xinjiang Uygur Autonomous Region from June 2010 to June 2020 were enrolled in this study, and these patients were randomly divided (ratio 1:1) into the ultrafiltration group (n=74) and the control group (n=74). All patients were treated with diuretics, cardiotonic, vasodilator and other comprehensive drugs according to relevant guidelines. After grouping, the patients in the control group were treated with standard treatment plan, while patients in the ultrafiltration group were treated with ultrafiltration on top of standard therapy. Diuretic drugs were discontinued during ultrafiltration, and intravenously furosemide (40 mg) was given immediately and 24 hours after the end of ultrafiltration. Clinical data including gender, age, complicated diseases, New York Heart Association (NYHA) function classification, etc. were collected. Effectiveness indicators include urine volume (the first 12-hour and 24-hour urine volume and the second 24-hour urine volume after using diuretic), body weight and dyspnea severity score. Safety indicators include systolic blood pressure, serum creatinine, serum Na+ concentration, blood K+ concentration and the number of deaths before and after intervention. Results: Two patients in the control group died due to worsening heart failure after randomization and were excluded in this study, 146 patients were finally analyzed (72 patients in the control group and 74 patients in the ultrafiltration group). There were 93 males, and the age was (68.3±11.2) years. There was no significant difference between patients in the ultrafiltration group and the control group in gender, age, body weight, course of disease, dyspnea severity score, NYHA function classification Ⅲ/Ⅳ, the proportion of patients with severe edema of both lower limbs, the proportion of patients with complicated diseases, and basic medication (all P>0.05). After using diuretics, the urine volume of the first 12-hour and 24-hour and the second 24-hour were significantly higher in the ultrafiltration group than in the control group (all P<0.05). Body weight decreased significantly after ultrafiltration treatment as compared with that before intervention in the ultrafiltration group (P<0.05). Compared with the control group, the dyspnea severity score was significantly improved in the ultrafiltration group (P<0.05). There was no significant difference in systolic blood pressure, serum creatinine, serum Na+ concentration, blood K+ concentration of patients between ultrafiltration group and control group before and after intervention (all P>0.05). During the clinical diagnosis and treatment, 2 male patients in the control group died, and the cause of death was aggravation of basic diseases complicated with acute heart failure and cardiogenic shock. There was no death in the ultrafiltration group, and there were no obvious clinical adverse events during and after ultrafiltration. Conclusion: Ultrafiltration therapy is safe and can improve diuretic sensitivity in heart failure patients with reduced ejection fraction and diuretic resistance.

Furosemida en el control de la hipertensión arterial posparto en preeclámpticas severas / Furosemide in the control of postpartum hypertension in severe preeclamptic women

RESUMEN OBJETIVO: Establecer la utilidad de la furosemida en el control de la hipertensión arterial posparto en preeclámpticas severa. MÉTODOS: Se realizó un estudio de casos y controles en el Hospital Central "Dr. Urquinaona", Maracaibo, Venezuela. Se incluyeron pacientes con preeclampsia severa, las cuales durante el posparto fueron asignadas al azar para ser tratadas con furosemida, alfametildopa y cloruro de potasio oral (grupo A) o alfa-metildopa oral (grupo B) por 48 horas. Los parámetros evaluados fueron: variaciones en los valores de presión arterial y frecuencia cardiaca, persistencia de hipertensión, parámetros de laboratorio y efectos adversos. RESULTADOS: Para el análisis final estaban disponibles los datos de 198 pacientes en el grupo A y 197 pacientes en el grupo B en cada uno de los grupos. Luego de 48 horas de tratamiento se observaron disminuciones estadísticamente significativas en los valores de presión arterial sistólica y diastólica entre las pacientes tratadas con furosemida y las pacientes del grupo control (p < 0,0001). Se observó persistencia de la hipertensión en 52 pacientes (26,3 %) del grupo A y en 134 pacientes (68,0 %) del grupo B (p < 0,0001). No se encontraron diferencias entre los grupos en la frecuencia cardiaca, valores de laboratorio y efectos adversos (p = ns). CONCLUSIÓN: La furosemida produce disminuciones significativas en los valores promedios de presión arterial sistólica y diastólica, al igual que en la frecuencia de persistencia de hipertensión postparto en preeclámpticas severas.

ABSTRACT OBJECTIVE: To establish the utility of furosemide in the control of postpartum blood pressure in severe preeclamptic patients. METHODS: A case-control study was conducted at the Central Hospital "Dr. Urquinaona", Maracaibo, Venezuela. Patients diagnosed with severe preeclampsia were included, who during the postpartum period were randomized to be treated with furosemide, alpha-methyldopa and oral potassium chloride (group A) or oral alpha-methyldopa (group B) for 48 hours. The parameters evaluated were: variations in blood pressure and heart rate values, the persistence of hypertension, laboratory parameters and adverse effects related to treatment. RESULTS: Data of 198 patients in group A and 197 patients in group B in each of the groups were available for the final analysis. After 48 hours of treatment, statistical significant decreases were observed in the values of systolic and diastolic blood pressure between patients treated with furosemide and patients in the control group (p <0.0001). Persistence of hypertension was observed in 52 patients (26.3 %) of group A and in 134 patients (68.0 %) of group B (p < 0.0001). No differences were found between the groups in heart rate, laboratory values and adverse effects (p = ns). CONCLUSION: Furosemide produces significant decreases in the mean values of systolic and diastolic blood pressure, as well as in the frequency of persistence of postpartum hypertension in severe preeclamptic patients.

Furosemide-induced pseudoporphyria in a patient with chronic kidney disease: case report / Pseudoporfiria induzida por furosemida em paciente com doença renal crônica: relato de caso

ABSTRACT Introduction: Pseudoporphyria is a rare photodermatosis with characteristics similar to those of porphyria cutanea tarda, without, however, presenting abnormalities in porphyrin metabolism. Its etiology is related to chronic kidney disease, ultraviolet radiation and certain medications. The aim of the present study is to describe a case of furosemide-related pseudoporphyria in a patient with chronic kidney disease. Case description: A 76-year-old male patient with stage 4 chronic kidney disease and in continuous use of furosemide presented ulcerated lesions with peripheral erythema and central hematic crust in the legs. On a skin infection suspicion, treatment with quinolone and neomycin sulfate was initiated, without improvement. A biopsy of the lesion was performed, with histopathological examination demonstrating findings compatible with porphyria, although the patient did not present high porphyrin levels. The diagnosis of furosemide-induced pseudoporphyria was then established, with medication suspension, and there was a significant improvement of the lesions. Discussion: There are few cases of pseudoporphyria described, but it is believed that this condition is underdiagnosed, especially in patients with chronic kidney disease. Both clinical and histopathological findings closely resemble porphyria, differentiating it from normal levels of porphyrin in plasma, urine, or feces. Conclusions: Although the lesions are mostly benign, they may increase the morbidity and mortality of these patients, so a proper diagnosis and early treatment are extremely important.

RESUMO Introdução: A pseudoporfiria é uma fotodermatose rara com características semelhantes às da porfiria cutânea tardia, sem, no entanto, apresentar anormalidades no metabolismo da porfirina. Sua etiologia está relacionada a doença renal crônica, radiação ultravioleta e determinados medicamentos. O objetivo do presente trabalho é descrever um caso de pseudoporfiria relacionada a furosemida em paciente portador de doença renal crônica. Descrição do caso: Paciente masculino, 76 anos, com doença renal crônica estágio 4 e em uso contínuo de furosemida, apresentou lesões ulceradas com eritema periférico e crosta hemática central nas pernas. Por suspeita de infecção de pele, foi iniciado tratamento com quinolona e sulfato de neomicina, sem melhora. Foi realizada então biópsia da lesão, com exame histopatológico demonstrando achados compatíveis com porfiria, sem, no entanto, o paciente apresentar níveis elevados de porfirinas. Foi então estabelecido o diagnóstico de pseudoporfiria induzida por furosemida, com suspensão de medicação , e houve melhora significativa das lesões. Discussão: Há poucos casos de pseudoporfiria descritos, mas acredita-se que essa condição seja subdiagnosticada, principalmente em pacientes com doença renal crônica. Tanto achados clínicos quanto histopatológicos se assemelham muito à porfiria, diferenciando desta por níveis normais de porfirina no plasma, na urina ou nas fezes. Conclusões: Embora as lesões sejam majoritariamente benignas, podem aumentar a morbimortalidade desses pacientes, por isso um diagnóstico adequado e tratamento precoce são de extrema importância.

Linfangiectasia intestinal primaria o enfermedad de Waldmann / Primary Intestinal Lymphangiectasia or Waldmann Disease

La linfangiectasia intestinal primaria en una patología infrecuente causada por la malformación de los conductos linfáticos intestinales. Normalmente se diagnostica antes de los 3 años de edad, pero puede aparecer en población adulta. Los síntomas más frecuentemente encontrados son la presencia de anasarca y dolor abdominal acompañado de malnutrición. El tratamiento es sintomático y se basa en la sustitución dietética de los triglicéridos de cadena larga por triglicéridos de cadena mediana con aumento del aporte proteico. En este trabajo se reporta el caso de una paciente femenina de 22 años de edad la cual presenta manifestación clínicas, imaginológicas y anatomopatológicas que permiten realizar el diagnóstico de una linfangiectasia intestinal primaria, caso extremadamente infrecuente y sobre todo a esta edad(AU)

Primary intestinal lymphangiectasia in an uncommon pathology caused by malformation of the intestinal lymphatic ducts. It is usually diagnosed before 3 years of age, but may appear in the adult population. The most frequent symptoms are the presence of anasarca and abdominal pain accompanied by malnutrition. The treatment is symptomatic and is based on the dietary substitution of long chain triglycerides by medium chain triglycerides with increased protein intake. This paper reports the case of a female patient of 22 years of age who presents clinical, imaging and anatomopathological manifestations that allow the diagnosis of primary intestinal lymphangiectasia, an extremely rare case, especially at this age(AU)

Predictors of mortality in a cohort of acute kidney injury patients / Preditores de mortalidade em uma coorte de pacientes com lesão renal aguda

BACKGROUND AND OBJETIVE: Acute kidney injury is related to high in-hospital mortality. The use of furosemide has been a controversial point in the prevention and treatment of acute kidney injury. The objective of this study was to identify predictors of mortality in critically ill patients with acute kidney injury with emphasis on use of furosemide. METHODS: A prospective cohort of 108 patients with acute kidney injury admitted consecutively in a intensive care unit and evaluated until death or hospital discharge. The dependent variable was death from any cause. The independent variables were age, sex, race, serum creatinine, potassium, admission diagnosis, urine output, volume infused, the twelve variables of Acute Physiology and Chronic Health disease Classification System II and furosemide use. We performed logistic regression analysis to identify predictors of death. RESULTS: The mean age of patients was 65.74 years with a predominance of women of African descent. The overall mortality rate was 44.4%. In logistic regression analysis, predictors of mortality were: using furosemide, age in years and Glasgow come scale. CONCLUSION: Use of furosemide was a predictor of mortality in a cohort of patients with acute kidney injury. The role of furosemide in the treatment and prevention of acute kidney injury certainly needs to be better evaluated...

JUSTIFICATIVA E OBJETIVO: A lesão renal aguda está relacionada a alta mortalidade intra-hospitalar. O uso de furosemida tem sido um ponto controverso em seu tratamento e sua prevenção. O objetivo deste estudo foi identificar preditores de mortalidade em pacientes gravemente enfermos com lesão renal aguda com ênfase para uso de furosemida. MÉTODOS: Coorte prospectiva de 108 portadores de lesão renal aguda admitidos consecutivamente em uma unidade de terapia intensiva e avaliados até o óbito ou a alta hospitalar. A variável dependente foi óbito por qualquer causa. As variáveis independentes foram: idade, gênero, raça, creatinina sérica, potássio, as 12 variáveis do Acute Physiology and Chronic Health Disease Classification System II (APACHE II), diagnóstico na admissão, débito urinário, volume infundido e uso de furosemida. Realizou-se análise de regressão logística para identificar os preditores de óbito. RESULTADOS: A média de idade dos pacientes foi de 65,74 anos com predomínio de mulheres afrodescendentes. A taxa de mortalidade global foi de 44,4%. Na análise de regressão logística, os preditores de mortalidade foram: uso de furosemida, idade em anos e escala de coma de Glasgow. CONCLUSÃO: Uso de furosemida foi preditor de mortalidade em uma coorte de portadores de lesão renal aguda. Seu papel no tratamento e na prevenção de lesão renal aguda certamente necessita ser mais bem avaliado...

Ascite no paciente cirrótico / Ascites in cirrhotic patient

Este artigo, ao fazer uma revisão da literatura no que tange ao tratamento da ascite no paciente com cirrose, enfatiza a importância da dieta com restrição de sal; do papel da espironolactona no início do tratamento em pacientes com um primeiro episódio de ascite e do tratamento combinado (espironolactona e furosemida) nas ascites recorrentes e da paracentese terapêutica, com reposição de albumina, na ascite tensa. Conclui ressaltando a importância da avaliação do transplante hepático nesta população de doentes.

The present article, reviewing medical literature regarding treatment of ascites in cirrhotic patients, emphasizes the importance of a sodium restricted diet; it also explains the role of espironolactone as the first treatment in a patient with the first episode of ascites, that of the combined treatment with espironolactone and furosemide in cases of recurrent ascites and that of therapeutical paracentesis with albumin replacement in patients with tense ascites. It concludes highlighting the importance of evaluating cirrhotic patients with ascites for liver transplantation.

Tratamiento médico de un hematoma subdural crónico / Medical treatment of a chronic subdural hematoma

Se presenta una paciente portadora de un hematoma subdural crónico postraumático, que se trató médicamente y se logró su desaparición en el curso de varios meses, sin tratamiento quirúrgico y sin signos evolutivos de empeoramiento neurológico. La furosemida fue usada como medicamento básico en su tratamiento. Se adjuntan imágenes que confirman el valor de este punto de vista terapéutico(AU)

This is the case of a patient carrier of a post-traumatic chronic subdural hematoma clinically treated achieving its disappearance over some months without surgical treatment and evolutionary signs of neurologic worsening. The furosemide was used as basic drug in its treatment. The images confirming the value of this point of therapeutical view are enclosed(AU)

Clinical evaluation of enalapril maleate and furosemide usage in dogs with degenerative myxomatous mitral valve, CHF functional class Ib / Avaliação clínica da utilização do maleato de enalapril e furosemida em cães com doença degenerativa mixomatosa da válvula mitral, classe funcional Ib

Degenerative myxomatous mitral valve (DMMV) is a heart disease of high incidence in small animal clinical medicine, affecting mainly older dogs and small breeds. Thus, a scientific investigation was performed in order to evaluate the clinical use of the medicines furosemide and enalapril maleate in dogs with this disease in CHF functional class Ib before and after the treatment was established. For this purpose 16 dogs with the given valve disease were used, separated into two groups: the first received furosemide (n=8) and the second received enalapril maleate (n=8) throughout 56 days. The dogs were evaluated in four stages (T0, T14, T28 and T56 day) in relation to clinical signs, hematological, biochemical and serum assessment, which included serum angiotensin converting enzyme (ACE) and aldosterone, as well as radiography, electrocardiography, Doppler-echocardiography and blood pressure. The results regarding the clinical, hematological and serum chemistry evaluations revealed no significant changes in both groups, but significant reductions in the values of ACE and aldosterone in the group receiving enalapril maleate were verified. The radiographic examination revealed reductions of VHS values and variable Pms wave of the electrocardiogram in both groups, but no changes in blood pressure values were identified. The echocardiogram showed a significant decrease of the variables LVDd/s in the studied groups and the FS percent in animals that received only enalapril. Therefore, analysis of results showed that monotherapy based on enalapril maleate showed better efficiency of symptoms control in patients with CHF functional class Ib.

A doença degenerativa mixomatosa da válvula mitral (DDMVM) é uma cardiopatia de alta incidência na clínica médica de pequenos animais, acometendo mormente cães idosos e raças de pequeno porte. Desta forma, foi realizada uma investigação científica objetivando avaliar clinicamente a utilização dos fármacos maleato de enalapril e furosemida em cães com a referida enfermidade na classe funcional Ib da ICC, antes e após a terapêutica implantada. Para isso, utilizaram-se 16 cães portadores da valvulopatia supracitada, distribuídos em dois grupos; com o primeiro recebendo furosemida (n=8) e o segundo maleato de enalapril (n=8), durante 56 dias. Os cães foram avaliados em quatro momentos (T0, T14, T28 e T56 dias) quanto aos sinais clínicos e parâmetros hematológicos e bioquímico-séricos, que incluíram concentrações séricas da enzima conversora da angiotensina (ECA) e aldosterona, como também avaliações radiográficas, eletrocardiográficas, ecodopplercardiográficas e da pressão arterial. Os resultados quanto aos parâmetros clínicos, avaliações hematológicas e bioquímicas séricas não revelaram alterações significativas em ambos os grupos, mas reduções significativas nos valores de ECA e aldosterona no grupo que recebeu o maleato de enalapril foram identificadas. Ao exame radiográfico observou-se reduções nos valores de VHS e na variável onda Pms do eletrocardiograma em ambos os grupos, mas sem alterações nos valores da pressão arterial. Por sua vez, o ecodopplercardiograma evidenciou diminuição significativa das variáveis DIVEd/s nos grupos estudados e na FEC por cento nos cães que receberam somente enalapril. Portanto, a análise dos resultados encontrados indicou que a monoterapia fundamentada no maleato de enalapril apresentou melhor eficiência no controle do quadro clínico em pacientes da classe funcional Ib da ICC.

Terapia antihipertensiva en enfermedad renal crónica / Treatment of hypertension in chronic kidney disease

La enfermedad renal crónica (ERC) constituye una de las causas más frecuentes de hipertensión arterial (HTA) secundaria. Existe una nueva clasificación de la ERC basada en la presencia de un daño estructural con o sin un deterioro de la velocidad de filtración glomerular (VFG). La prevalencia de la HTA varía principalmente según la magnitud de la VFG y la etiología de la enfermedad del parénquima renal. Los mecanismos hipertensógenos primordiales son: la retención de sodio e hipervolemia, y la activación del eje renina angiotensina aldosterona. La HTA es también un factor de progresión de la ERC. La terapia se basa en la restricción de sodio, diuréticos y bloqueadores del eje renina angiotensina. Consideraciones farmacológicas y clínicas son fundamentales para un efectivo uso de esta terapia. Los objetivos son la prevención cardiovascular y renal, a través de la obtención de determinados niveles de presión arterial (PA).

Chronic kidney disease (CKD) is one of the most common causes of secondary hypertension (HTN). Currently, there is a new classification of CKD based on the presence of structural damage with or without glomerular filtration rate(GFR) deterioration. The prevalence of HTN in CKD varies mainly depending on the magnitude of the GFR and the etiology of renal parenchymal disease. Main hipertensive mechanisms are: salt retention with fluid overload, and reninangiotensin aldosterona axis activation. HTN is also a factor for CKD progression. The current therapy is based on sodium restriction, diuretics and renin angiotensin system blockers. Pharmacological and clinical precautions are essential foran effective use of this therapy. Objectives are to prevent cardiovascular and renal events, through obtaining certain blood pressure (BP) levels.

Syringomyelia in three small breed dogs secondary to Chiari-like malformation: clinical and diagnostic findings

Three small breed dogs were referred for the evaluation of neurologic deficits. Upon physical and neurologic examination, all dogs displayed hyperesthesia, pain, and neck stiffness. Magnetic resonance imaging was performed on the brain and spinal cord, and all three dogs presented Chiari-like malformations and syringomyelia. These dogs were treated with prednisolone and furosemide, and showed rapid improvement of clinical signs. Chiari malformations and syringomyelia were not improved because of congenital disorders. This case report demonstrates the clinical and diagnostic features of Chiari-like malformations and syringomyelia in three small breed dogs.

Asymmetric pulmonary edema after scorpion sting: a case report / Edema pulmonar assimétrico após picada de escorpião: relato de caso

A 12-year-old boy was referred with acute asymmetric pulmonary edema (APE) four-hour after scorpion sting to Emergency department. On admission, the main clinical manifestations were: dyspnea, tachypnea, and tachycardia. Chest x-ray revealed APE predominantly on the right hemithorax. The patient was treated with oxygen, intravenous frusemide and digoxin and discharged on the sixth hospital day in a good condition. This case report emphasizes the occurrence of asymmetric pulmonary edema after severe scorpion envenomation within few hours immediately after the sting.

Menino de 12 anos foi internado no Pronto Socorro, com edema pulmonar assimétrico agudo (APE), quatro horas após picada de escorpião. À admissão, as principais manifestações clínicas foram: dispnéa, taquipnéa e taquicardia. Raio X do pulmão revelou APE predominantemente no hemitórax direito. O paciente foi tratado com oxigênio, frusemida intravenosa e digoxina e teve alta no sexto dia de internação, em boas condições. Este relato de caso enfatiza a ocorrência de edema pulmonar assimétrico algumas horas após a picada.

Posterior circulation stroke in a young male following snake bite.

Neurological deficits can occur following snake bite. It is usually due to intracerebral haemorrhage or subarachnoid bleed as a result of depletion of clotting factors. A healthy 14-years-old male developed bilateral ptosis and altered sensorium within 3 hours of snake bite. CT Brain revealed bilateral cerebellar and right occipital infarction with mass effect. Clotting time and bleeding time were normal. The possible mechanism for infarction in this patient is discussed.

Hemophagocytic syndrome in Dengue hemorrhagic fever with severe multiorgan complications.

A 46 year old woman who presented with severe multiorgans involvement including liver brain, cardio-pulmonary failure, gastrointestinal bleeding, progressive cytopenia, DIC and hemophagocytic syndrome during the convalescent phase of Dengue type II has been successfully treated primarily with pulse methyl prednisolone and high dose intravenous immunoglobulin G. The authors believe that HPCS are not infrequently seen with high mortality and recommended early diagnosis and treatment with the regimen. This is the first complete report of hemophagocytic syndrome in adult dengue hemorrhagic fever in Thailand. The literature of HPCS in DHF was reviewed and discussed.

Influência da terapia com diuréticos nos níveis séricos de tiamina em pacientes com insuficiência cardíaca / Influence of diuretic therapy on thiamin blood levels in patients with heart failure

Fundamento - A importância de micronutrientes como tiamina há muito é conhecida, visto que sua deficiência associa-se com insuficiência cardíaca (IC) de alto débito. Vários trabalhos mostram a influência dos diuréticos nos níveis de tiamina. Objetivos - Avaliar se o uso de furosemida isolada ou associada a espironolactona (espiro) determina níveis de tiamina diferentes em pacientes (pc) com IC. Verificar se a tiamina é influenciada por fatores nutricionais, comorbidades e outros fármacos. Métodos - Estudo em duas etapas: Estudo 1 - análise transversal (uso prévio de furosemida isoladamente ou em associação com espiro) de 22 pc com IC (classes III/IV da NYHA) divididos em: grupo I - com epiro (n=11) e grupo II - sem espiro (n=11); Estudo 2 - ensaio clínico randomizado, aberto, com três grupos paralelos de 53 pc com IC divididos em grupo "sem diuréticos" (n=15), "com diurético" (n=15) (uso de furosemida até o dia 90 e depois associar espiro até o dia 180) e "com espiro" (n=23) (usar furosemida e espiro desde a visita inicial até o dia 180). Os pc realizaram três visitas: inicial, em 90 dias e 180 dias, sendo coletadas amostras de sangue para tiamina e outros exames, assim como análise clínica. Determinamos os níveis de tiamina por recombinação de apoenzima e por cromatografia líquida de alta performance. Utilizamos testes t de Student, qui-quadrado, Mann-Whitney, Kruskal-Wallis, Spearman e como a variância foi cerca de três vezes maior que a estimada, usamos a simulação robusta de Monte Carlo. Resultados: no estudo 1, os grupos I e II eram similares em relação à ingesta alimentar, doses diárias de furosemida (I=110,9 +- 30,2 vs II=105,5 +-26,9mg; p>0,05) e dados demográficos. Os pacientes do grupo I mostraram níveis maiores de tiamina (277,2+-89,8), comparados aos do grupo II (154,7+-35,7) (p<0,001). Nenhuma outra variável esteve associada com a tiamina. No estudo 2, os grupos também eram semelhantes quanto às características clínicas e laboratoriais...

Background: The importance of micronutrients such as thiamine known since its deficiency is associated with the development of high-output heart failure (HF). Several studies show the influence of diuretic therapy in thiamine blood levels. Objectives: assess whether the use of furosemide alone or in combination with spironolactone (spiro) can determine different thiamine blood levels in patients (pt) with HF. To determinat whether thiamine blood levels were influenced by nutritional factors, comorbidities and other drugs. Methods: Study 1 - cross-sectional analysis (previous use of furosemide alone or with spiro) of 22 HF pt (NYha class III/IV) divided in two groups: I - with spiro (n=11) and II - without spiro (n=11); Study 2 - randomized, open-label, with three parallel groups of 53 HF pt divided into group "without diuretics" (n=15), "with diuretic" (n=15) (use of furosemide until day 90 and then adding spiro from day 90 until day 180) and "with spiro" (n=23) (using furosemide and spiro through all study). Patients were scheduled to three visits: day 0, day 90 and day 180, and blood samples were collected for thiamine and other tests, as well as clinical analysis. Thiamine levels were determined using an apoenzyme recombination method and high-performance liquid chromatography. The tests used were t-Student, chi-square, Mann-Whitney, Kruskal-Wallis, Spearman correlation, and as the variance was about three times higher than estimated, we used a robust Monte Carlo simulation. Results: in study 1, group I and II were similar regarding food intake, daily furosemide doses (I=110.9+-30.2 vs II=105.5+-26.9 mg; p>0.05) and demographics. Pts in group I (277.2+-89.8) showed significantly higher thiamine levels when compared to pts in group II (154.7+-35.7) (p<0.001). No other variables were associated with thiamine. In study 2, the groups were also similar regarding clinical and laboratory assessments. We found no statistical differences in thiamin blood levels...

Solução salina hipertônica para prevenção de insuficiência renal em pacientes com insuficiência cardíaca descompensada e hiponatremia / Hypertonic saline solution for renal failure prevention in patients with decompensated heart failure

FUNDAMENTO: Hiponatremia e fenômenos congestivos indicam mau prognóstico na insuficiência cardíaca descompensada. A ocorrência de insuficiência renal está associada a aumento do risco de morte. OBJETIVO: Avaliar a segurança e a eficácia da solução hipertônica em pacientes com insuficiência cardíaca descompensada para prevenção de insuficiência renal. MÉTODOS: Participaram do estudo pacientes com insuficiência cardíaca descompensada, congestão e hiponatremia. Além do tratamento padrão, os pacientes receberam solução salina hipertônica, e foram submetidos a avaliação tanto clínica como laboratorial. RESULTADOS: Foram incluídos 9 pacientes. A média das idades dos pacientes foi de 55 + 14,2 anos, sendo 5 (55,5 por cento) do sexo masculino e 4 (44,5 por cento), do feminino. Todos apresentavam classe funcional III-IV da New York Heart Association (NYHA), e 5 (55,5 por cento) recebiam dobutamina. Todos apresentaram creatinina inicial acima de 1,4 mg/dl. A tonicidade média da solução foi de 4,39 por cento + 0,018 por cento (2,5 por cento a 7,5 por cento) e a duração do tratamento foi de 4,9 dias + 4,1 dias (1 dia a 15 dias). Não houve efeitos adversos graves; em nenhum caso houve piora clínica ou distúrbios neurológicos; hipocalemia ocorreu em 4 (44,5 por cento) casos. A comparação das variáveis pré- e pós-tratamento demonstrou queda da uréia (105 mg/dl + 74,8 mg/dl vs. 88 mg/dl + 79,4 mg/dl; p = 0,03) e aumento do volume urinário (1.183 ml/dia vs. 1.778 ml/dia; p = 0,03); houve tendência a redução da creatinina (2,0 mg/dl + 0,8 mg/dl vs. 1,7 mg/dl + 1,0 mg/dl; p = 0,08). Apesar da elevação do valor do sódio (131 mEq/l + 2,8 mEq/l vs. 134 mEq/l + 4,9 mEq/l) e da redução do peso (69,5 kg + 18,6 kg vs. 68,2 kg + 17,1 kg), não houve diferença estatisticamente significante. CONCLUSÃO: O uso de solução salina hipertônica em pacientes com insuficiência cardíaca descompensada pode ser método terapêutico seguro e potencialmente relacionado a melhora...

BACKGROUND: Hyponatremia and congestive phenomena indicate a bad prognosis in decompensated heart failure. The occurrence of renal failure is associated to an increased death risk. OBJECTIVE: To evaluate the safety and efficacy of the hypertonic saline solution in patients with decompensated heart failure for renal failure prevention. METHODS: Patients with decompensated heart failure, congestion and hyponatremia participated in the study. In addition to the standard treatment, the patients received hypertonic saline solution and were submitted to clinical as well as laboratory assessment. RESULTS: Nine patients were enrolled in the study. Mean age was 55 + 14.2 years, being 5 male (55.5 percent) and 4 (44.5 percent) female patients. All of them presented functional class III-IV of the New York Heart Association (NYHA), and 5 (55.5 percent) received dobutamine. All of them presented initial creatinine > 1.4 mg/dl. The mean tonicity of the solution was 4.39 percent + 0.018 percent (2.5 percent to 7.5 percent) and the duration of treatment was 4.9 days + 4.1 days (1-15 days). There were no severe adverse effects; none of the patients presented clinical worsening or neurologic disorders; hypokalemia occurred in 4 cases (44.5 percent). The comparison of the variables before and after treatment showed a decrease in urea (105 mg/dl + 74.8 mg/dl vs. 88 mg/dl + 79.4 mg/dl; p = 0.03) and increase in the urinary volume (1,183 ml/day vs. 1,778 ml/day; p = 0.03); there was no tendency to creatinine decrease (2.0 mg/dl + 0.8 mg/dl vs. 1.7 mg/dl + 1.0 mg/dl; p = 0.08). Despite the elevation in sodium levels (131 mEq/l + 2.8 mEq/l vs. 134 mEq/l + 4.9 mEq/l) and weight decrease (69.5 kg + 18.6 kg vs. 68.2 kg + 17.1 kg), there was no statistically significant difference. CONCLUSION: The use of hypertonic saline solution in patients with decompensated heart failure can be a safe therapeutic method and potentially related to clinical improvement and renal...

Could garlic be an useful adjuvant therapy in adriamycin heart failure?

50 year old suffering from breast carcinoma, treated with adriamycin developed heart failure with 22.82% ejection fraction. Added garlic pearl to routine anti-failure measures for 9 months to achieve 51.6% ejection fraction.